IN-HOSPITAL OR OUT-OF-HOSPITAL INITIATION OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN IN PATIENTS WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION AFTER A WORSENING HEART FAILURE EVENT: THE PARAGLIDE-HF TRIAL
Nouhravesh N, Erickson T, Cyr D, Hernandez A, Morrow D, Velazquez E, Ward J, Williamson K, Starling R, Zieroth S, Solomon S, Braunwald E, Mentz R. IN-HOSPITAL OR OUT-OF-HOSPITAL INITIATION OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN IN PATIENTS WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION AFTER A WORSENING HEART FAILURE EVENT: THE PARAGLIDE-HF TRIAL. Journal Of The American College Of Cardiology 2024, 83: 377. DOI: 10.1016/s0735-1097(24)02367-2.Peer-Reviewed Original ResearchSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysis